Brief: ADC Therapeutics Announces Positive Initial Data From Lotis-7 Clinical Trial Evaluating Zynlonta® In Combination With Bispecific

ADC Therapeutics SA

11/12/2024 13:32

Dec 11 (Reuters) - ADC Therapeutics  ADCT.N :
    * ADC THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA FROM
LOTIS-7
CLINICAL TRIAL EVALUATING ZYNLONTA® IN COMBINATION WITH
BISPECIFIC ANTIBODY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE
LARGE B-CELL LYMPHOMA
    * ADC THERAPEUTICS SA - ZYNLONTA PLUS GLOFITAMAB SHOWS 94%
ORR AND
72% CR RATE
    * ADC THERAPEUTICS SA - NO DOSE-LIMITING TOXICITIES OR
HIGH-GRADE
CRS/ICANS OBSERVED

Source text:  ID:nPn7x6p8Ma 
Further company coverage:  ADCT.N 

 ((Reuters.Briefs@thomsonreuters.com;))